Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.

@article{Graham1999Rhenium186labeledHD,
  title={Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.},
  author={Martin C. Graham and Howard I. Scher and Guang Bin Liu and Samuel D. J. Yeh and Tracey Curley and Farhad Daghighian and Stanley J. Goldsmith and Steven M. Larson},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1999},
  volume={5 6},
  pages={1307-18}
}
Rhenium-186 (tin)-labeled hydroxyethylidene diphosphonate (186Re-labeled HEDP) was evaluated in 27 men with progressive androgen-independent prostate cancer and bone metastases. Administered activities ranged from 1251 to 4336 MBq (33.8-117.2 mCi). The primary objectives were to assess tumor targeting, normal organ dosimetry, and safety. Antitumor effects were assessed by posttherapy changes in prostate-specific antigen and, when present, palliation of pain. Whole-body kinetics, blood and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Monte Carlo and analytical calculations of dose distributions in craniopharyngioma cysts treated with radiocolloids containing 32P or 186Re.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine • 2009
View 3 Excerpts
Highly Influenced

EANM procedure guideline for treatment of refractory metastatic bone pain

European Journal of Nuclear Medicine and Molecular Imaging • 2008

Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2004
View 1 Excerpt

The Biology of Skeletal Metastases

Cancer Treatment and Research • 2004

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 1991
View 4 Excerpts
Highly Influenced

Cytotoxic chemotherapy for advanced prostate cancer : does it work , and if so , how do we prove it ?

H. I. Scher
ASCO Educational Book • 1998

Cytotoxic chemotherapy for advanced prostate cancer: does it work, and if so, how do we prove it? ASCO

H. I. Scher
1998
View 1 Excerpt

Superiority of suramin 1 hydrocortisone (S1H) over placebo 1 hydrocortisone (P1H): results of a multicenter double-blind phase III study in patients with hormone refractory prostate cancer

E. J. Small, M. E. Marshall, +6 authors M. Eisenberger
(HRPC). Proc. Am. Soc. Clin. Oncol.,19: • 1998
View 1 Excerpt

A new method of marrow dosimetry integrating cellularity volume , and isotope activity measurements using chemical shift NMR images registered with SPECT and for PET : initial phantom results

M. C. Graham, D. Ballon, J. A. Koutcher, E. Schneider, S. M. Larson
Med . Phys . • 1994

A new method of marrow dosimetry integrating cellularity volume, and isotope activity measurements using chemical shift NMR images registered with SPECT and for PET: initial phantom

M. C. Graham, D. Ballon, J. A. Koutcher, E. Schneider, S. M. Larson
results, Med. Phys., • 1994
View 1 Excerpt

Bone metastases: biology and therapy

H. I. Scher, L.W.K. Chung
Semin. Oncol., • 1994
View 1 Excerpt

Similar Papers

Loading similar papers…